Drug intelligence / Profile preview

YDB201

Development stage: Preclinical
Lead developer: YD Global Life Science

Overview

YDB201 is an early-stage drug candidate under development by YD Global Life Science. It is currently in the 'Hit' stage of preclinical research, targeting multiple undisclosed biological pathways for the treatment of diseases in the fields of ophthalmology and oncology. As a multi-target therapeutic, it is designed to address complex disease pathologies by modulating several targets simultaneously, though its specific modality (e.g., small molecule or biologic) and molecular targets have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on YDB201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YDB201.

Explore the full profile